At the time of writing, Arrowhead Pharmaceuticals Inc [ARWR] stock is trading at $61.44, down -4.98%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ARWR shares have gain 16.58% over the last week, with a monthly amount glided 52.42%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arrowhead Pharmaceuticals Inc [NASDAQ: ARWR] stock has seen the most recent analyst activity on June 05, 2024, when Goldman initiated its Neutral rating and assigned the stock a price target of $31. Previously, BofA Securities started tracking the stock with Buy rating on December 04, 2023, and set its price target to $29. On September 19, 2023, Citigroup initiated with a Neutral rating and assigned a price target of $33 on the stock. TD Cowen started tracking the stock assigning an Outperform rating. SVB Securities downgraded its rating to a Market Perform but $40 remained the price target by the analyst firm on May 12, 2023. SMBC Nikko started tracking with an Outperform rating for this stock on April 26, 2023, and assigned it a price target of $80. In a note dated April 12, 2023, SVB Securities upgraded an Outperform rating on this stock and boosted its target price from $21 to $35.
For the past year, the stock price of Arrowhead Pharmaceuticals Inc fluctuated between $9.57 and $67.14. Currently, Wall Street analysts expect the stock to reach $66.5 within the next 12 months. Arrowhead Pharmaceuticals Inc [NASDAQ: ARWR] shares were valued at $61.44 at the most recent close of the market. An investor can expect a potential return of 8.24% based on the average ARWR price forecast.
Analyzing the ARWR fundamentals
Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -0.18%, Pretax Profit Margin comes in at -0.26%, and Net Profit Margin reading is -0.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.41 and Total Capital is -0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.37.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 59.73 points at the first support level, and at 58.02 for the second support level. However, for the 1st resistance point, the stock is sitting at 63.71, and for the 2nd resistance point, it is at 65.99.
Ratios To Look Out For
It is important to note that Arrowhead Pharmaceuticals Inc [NASDAQ:ARWR] has a current ratio of 4.86. In addition, the Quick Ratio stands at 4.86 and the Cash Ratio stands at 0.67. Considering the valuation of this stock, the price to sales ratio is 10.06, the price to book ratio is 17.89.
Transactions by insiders
Recent insider trading involved Michael Perry, Director, that happened on Dec 05 ’25 when 16250.0 shares were purchased. Director, Ferrari Mauro completed a deal on Nov 28 ’25 to sell 8750.0 shares. Meanwhile, Director Mauro Ferrari bought 8750.0 shares on Nov 28 ’25.
